Literature DB >> 606633

Changes in the plasma clearance and protein binding of carbenoxolone with age, and their possible relationship with adverse drug effects.

M J Hayes, M Sprackling, M J Langman.   

Abstract

Comparison by equilibrium dialysis of plasma protein binding sites for carbenoxolone in people under 40 years of age and in people over 65 years of age showed that the number of binding sites was reduced in the elderly and that this fall was associated with a reduction in plasma albumin levels. Although carbenoxolone has some aldosterone-like effects, these properties could not be shown to be due to displacement of aldosterone from its protein binding sites by competitive protein binding of carbenoxolone. Single doses of carbenoxolone were found to be removed considerably more slowly from the plasma of elderly individuals than from the young. The results of these three series of experiments suggest that the side-effects of carbenoxolone in the elderly may in part be caused by reduced protein binding, leaving more free drug in the active unbound form, and in part by reduced hepatic clearance mechanisms.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 606633      PMCID: PMC1411850          DOI: 10.1136/gut.18.12.1054

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  15 in total

1.  TREATMENT OF GASTRIC ULCER WITH CARBENOXOLONE SODIUM AND OESTROGENS.

Authors:  R DOLL; I D HILL; C F HUTTON
Journal:  Gut       Date:  1965-02       Impact factor: 23.059

2.  Changes in drug metabolism with increasing age: 1. warfarin binding and plasma proteins.

Authors:  M J Hayes; M J Langman; A H Short
Journal:  Br J Clin Pharmacol       Date:  1975-02       Impact factor: 4.335

3.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

4.  Problems of interpretation of laboratory findings in the old.

Authors:  F I Caird
Journal:  Br Med J       Date:  1973-11-10

5.  The absorption and excretion of carbenoxolone in man.

Authors:  H D Downer; R W Galloway; L Horwich; D V Parke
Journal:  J Pharm Pharmacol       Date:  1970-07       Impact factor: 3.765

6.  Complications of carbenoxolone therapy.

Authors:  G J Davies; J Rhodes; B J Calcraft
Journal:  Br Med J       Date:  1974-08-10

7.  The effect of carbenoxolone on the subcellular distribution of ( 3 H) aldosterone in rat kidney.

Authors:  M J Humphrey; E Lindup; D V Parke; J Chakraborty
Journal:  Biochem J       Date:  1972-11       Impact factor: 3.857

8.  Quantitative and qualitative aspects of the plasma protein binding of carbenoxolone, an ulcer-healing drug.

Authors:  D V Parke; W E Lindup
Journal:  Ann N Y Acad Sci       Date:  1973-11-26       Impact factor: 5.691

9.  A gas chromatographic determination of carbenoxolone in human serum.

Authors:  C Rhodes; P A Wright
Journal:  J Pharm Pharmacol       Date:  1974-11       Impact factor: 3.765

10.  Changes in drug metabolism with increasing age: 2. phenytoin clearance and protein binding.

Authors:  M J Hayes; M J Langman; A H Short
Journal:  Br J Clin Pharmacol       Date:  1975-02       Impact factor: 4.335

View more
  7 in total

Review 1.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

2.  Population pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients.

Authors:  Partha Nandy; Mahesh N Samtani; Rachel Lin
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

Review 3.  Plasma protein binding of drugs in the elderly.

Authors:  S M Wallace; R K Verbeeck
Journal:  Clin Pharmacokinet       Date:  1987-01       Impact factor: 6.447

4.  Adverse effects of anti-ulcer drugs.

Authors:  D A Henry; M J Langman
Journal:  Drugs       Date:  1981-06       Impact factor: 9.546

5.  Modulating membrane fluidity corrects Batten disease phenotypes in vitro and in vivo.

Authors:  Mark L Schultz; Luis Tecedor; Elena Lysenko; Shyam Ramachandran; Colleen S Stein; Beverly L Davidson
Journal:  Neurobiol Dis       Date:  2018-04-13       Impact factor: 7.046

6.  Encapsulated Carbenoxolone Reduces Lung Metastases.

Authors:  Adi Karsch-Bluman; Shimrit Avraham; Miri Assayag; Ouri Schwob; Ofra Benny
Journal:  Cancers (Basel)       Date:  2019-09-17       Impact factor: 6.639

7.  Effects of Carbenoxolone on the Canine Pituitary-Adrenal Axis.

Authors:  Takahiro Teshima; Hirotaka Matsumoto; Tomoko Okusa; Yumi Nakamura; Hidekazu Koyama
Journal:  PLoS One       Date:  2015-08-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.